IGF2 and central nervous system cancer: To further understand how the Igf2 amplified glioma model, mBT0309, shapes the TME over time, we performed multiplex IMC using a custom 33-antibody neuro-immuno-oncology panel on a time course of tumor development (Figure 6A, Figure S7A).